8-K: Masimo Reports Strong First Quarter 2025 Results, Updates Full-Year Guidance

Masimo Corporation announced its first quarter 2025 financial results, showcasing double-digit revenue growth and significant earnings growth, while also updating its full-year 2025 guidance to reflect the impact of new tariffs.

Summary

• Masimo Corporation reported its financial results for the first quarter ended March 29, 2025.
• GAAP revenue was $372 million, representing a 10% increase.
• Non-GAAP revenue was $371 million, also representing a 10% increase on a constant currency basis.
• GAAP net income per diluted share was $0.86.
• Non-GAAP net income per diluted share was $1.36, a 56% increase compared to the prior year period.
• GAAP loss from discontinued operations, net of tax, was ($218) million, including an impairment of intangibles of $295 million for the non-healthcare consumer business.
• The company updated its 2025 outlook for continuing operations.
• Non-GAAP revenue is projected to be $1,500 to $1,530 million, an 8% to 11% increase on a constant currency basis.
• Excluding the impact of new tariffs, Non-GAAP operating profit is expected to be $420 to $436 million, with a Non-GAAP operating margin of 28.0% to 28.5%, and Non-GAAP earnings per diluted share of $5.30 to $5.60.
• Including the impact of new tariffs, Non-GAAP operating profit is projected to be $383 to $403 million, with a Non-GAAP operating margin of 25.5% to 26.4%, and Non-GAAP earnings per diluted share of $4.80 to $5.15.
• The company is developing mitigation plans to address the impact of new tariffs.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong Q1 results and updated guidance. However, the impact of new tariffs introduces some uncertainty, tempering the overall sentiment.

Positives

• Masimo achieved double-digit revenue growth in Q1 2025.
• Non-GAAP earnings per share saw a significant increase of 56%.
• The company is actively working on mitigation plans to address the impact of new tariffs.
• Incremental value of new contracts was $77 million.
• Unrecognized contract revenue was $1,762 million.
• Consumable and Service revenue of $320 million grew 8% on a constant currency basis.
• Capital and Other revenue of $51 million grew 32% on a constant currency basis.

Negatives

• GAAP loss from discontinued operations was ($218) million, including a $295 million impairment of intangibles.
• New tariffs are expected to negatively impact operating profit and earnings per share.
• The implementation of tariffs remains a dynamic and uncertain situation that could cause actual results to be materially different from projections and forecasts.

Risks

• The company faces risks related to dependence on Masimo SET and Masimo rainbow SET products and technologies.
• There is a risk of intellectual property claims and the highly competitive nature of the markets.
• Failure to continue developing innovative products and technologies could impact future performance.
• The company is exposed to risks associated with obtaining regulatory approval of current and future products and technologies.
• New international trade tariffs and changes in general economic conditions pose potential risks.
• The company is involved in ongoing litigation and related matters.

Future Outlook

Masimo expects Non-GAAP revenue of $1,500 to $1,530 million for 2025, representing an 8% to 11% increase on a constant currency basis; however, this guidance is impacted by new tariffs, which the company is working to mitigate.

Management Comments

• Katie Szyman, Chief Executive Officer of Masimo, stated that the company's technology advantage is real and that the team is enthusiastic about the path forward.
• She also noted that the first quarter results demonstrate the earnings power of the core business.

Industry Context

Masimo operates in the highly competitive medical technology industry, facing competition from companies offering patient monitoring solutions and pulse oximetry technologies. The company's focus on innovation and expansion into new markets is crucial for maintaining its competitive edge.

Comparison to Industry Standards

• Masimo's growth in Non-GAAP earnings per share of 56% significantly outpaces the average growth rate of its competitors in the medical device industry, such as Medtronic and Stryker, which typically see EPS growth in the single to low double-digit percentages.
• The company's Non-GAAP operating margin of 28.8% is also higher than the industry average, indicating strong operational efficiency.
• Compared to Philips Healthcare and GE Healthcare, Masimo's focus on non-invasive monitoring and connectivity solutions positions it well in the evolving healthcare landscape.

Legal Proceedings

• Masimo is engaged in various legal proceedings against Apple since January 2020, including proceedings in federal courts, the U.S. Patent and Trademark Office, and the U.S. International Trade Commission.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the effect of new tariffs.
• Employees may be affected by changes in operations and product sourcing related to tariff mitigation.
• Customers may experience changes in product pricing or availability due to tariffs.
• Suppliers may be impacted by adjustments in product sourcing.

Next Steps

• The company will continue to develop and implement mitigation plans to address the impact of new tariffs.
• Masimo will reassess and modify its plans as the tariff situation evolves.
• The company will focus on adjusting product sourcing and operations to mitigate the impact of tariffs.

Key Dates

Keywords

Masimo, financial results, revenue, earnings, tariffs, guidance, healthcare, technology, pulse oximetry, monitoring